Resmed reports 11% increase in revenues for Q2 

SAN DIEGO – Resmed reported revenue increased 11% to $1.4 billion for its second quarter of fiscal year 2026. 

Other financial results: 

• Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps to 62.3%. 
• Income from operations increased 18%; non-GAAP income from operations up 19%. 
• Diluted earnings per share of $2.68; non-GAAP diluted earnings per share of $2.81. 
• Operating cash flow of $340 million. 

“Our second quarter results demonstrate the strength and resilience of our global business as we continue advancing our mission to help people sleep better, breathe better, and live longer and healthier lives in the comfort of their own home,” said Chairman and CEO Mick Farrell. “Year-over-year, we delivered 11% headline revenue growth, 310 basis points of non‑GAAP gross margin expansion, and continued operating excellence, resulting in another quarter of mid-teens non‑GAAP EPS growth. These results reflect strong ongoing demand for our market‑leading sleep and respiratory care devices, as well as the growing impact of our digital health ecosystem that spans more than 140 countries.” 

In the second quarter, Resmed recorded $6 million of restructuring-related charges as part of company-wide workforce planning activities that started in the first quarter.  

Resmed also reported: 

• Revenue in the U.S., Canada, and Latin America, excluding Residential Care Software, grew by 11%. 
• Revenue in Europe, Asia, and other markets, excluding Residential Care Software, grew by 6% on a constant currency basis. 
• Residential Care Software revenue increased by 5 % on a constant currency basis